Forbes January 22, 2026
One of the most dramatic improvements in cancer therapy over the past several years has been the adoption of cell-based therapies. Many of these involve CAR T therapies—treatments in which immune system cells are modified to attack cancer cells. To date, the great majority of these therapies have used the patient’s own immune cells: the cells are extracted, modified, expanded and then reinfused.
The good news is that some of these therapies have had remarkable results. Nonetheless, there are significant barriers to their widespread adoption. These include variability in patients’ cells, the time required for extraction, modification, expansion, reinfusion and patient preparation. This results in substantial delays between diagnosis and effective treatment, as well as extremely high costs that can...
Today's Sponsors
Today's Sponsor